CA-PERSONALIS
17.12.2020 15:09:10 CET | Business Wire | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its Systematic HLA Epitope Ranking Pan Algorithm (SHERPA), the company’s proprietary, machine learning-based tool for the comprehensive identification and characterization of cancer neoantigens. Integrated into the Personalis® NeXT Platform™, SHERPA enables the development of new neoantigen-based diagnostic biomarkers, such as the company’s proprietary Neoantigen Presentation Score (NEOPS™), and novel personalized therapies.
Data presented at the SITC Annual Meeting in November 2020 showed SHERPA outperforming commonly used neoantigen binding prediction tools in clinical tumor samples. “With more accurate neoantigen presentation prediction, we are looking to enable a new generation of precision oncology applications,” said Richard Chen, MD, Personalis CSO. “Trained on a proprietary immunopeptidomics dataset derived from engineered cell lines, SHERPA improves neoantigen presentation prediction compared to other in silico methods. With this advancement, SHERPA can enable more predictive biomarkers for cancer therapy as well as facilitate the development of neoantigen-targeting, personalized cancer therapies. Our recently-launched NEOPS is one example of a SHERPA-derived composite biomarker that has shown promise in predicting immunotherapy response in cancer patients.”
While most conventional in silico methods generally only assess the potential MHC-binding affinity and stability of identified peptides, SHERPA goes a step further by incorporating features relating to the antigen processing machinery and RNA abundance to generate a presentation rank for each detected peptide. This serves to determine the relative likelihood of a given neoantigen being presented and undergoing immunosurveillance.
This launch represents the broader commercial release of SHERPA, which is currently being leveraged by Personalis’ preferred partner, Sarepta Therapeutics, to characterize immune response to precision genetic therapeutics in patients with rare diseases, demonstrating the applicability of this machine learning tool in disease areas beyond cancer.
About Personalis, Inc.
Personalis, Inc. is a leader in cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc ).
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of SHERPA, NEOPS or the Personalis NeXT Platform, the company’s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005355/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Adaptive announces strategic investment from HSBC and Citi to fuel capital markets technology innovation5.3.2026 14:01:00 CET | Press release
Investment capitalizes on significant technological shifts in capital markets driven by cloud, open-source and AIFunding to scale Adaptive’s development of next-gen cloud-enabled front office solutions, centered around its Aeron® technology Adaptive, a leader in custom trading technology solutions, announces it has secured strategic investment from two prominent global financial institutions, Citi and HSBC. This funding is set to significantly accelerate Adaptive’s growth and product innovation roadmap. The strategic backing from HSBC and Citi underscores the collaboration between Adaptive and two of the world’s largest financial institutions on strategic initiatives to reshape capital markets technology. It will enable Adaptive to capitalize on significant technological disruption and meet the growing demand for client‑owned, differentiated and bespoke trading technology. Centered around Adaptive’s suite of Aeron®products, the funding allows the company to scale its delivery of high-p
CPAC Systems AB Chooses RideController, Inc. Accelerating Intelligent Boat Innovation5.3.2026 14:00:00 CET | Press release
CPAC Systems AB today announces a partnership between its premium marine integration platform Marivue and RideController, Inc. RideController becomes an Integrated Experience Partner within the Marivue ecosystem, advancing integration, automation, and user experience for next generation watersports and recreational boats. The partnership combines Marivue’s digital dashboard, integrated boat architecture, and Horizon cloud platform with RideController’s next generation power distribution and LED control systems. Together, the companies will deliver a fully integrated electrical and lighting experience for watersports and premium recreational vessels. Rather than treating switching and lighting as separate subsystems, the collaboration establishes a cohesive digital and electrical backbone. RideController’s distributed solid state power and advanced LED control technology will integrate into Marivue products, enabling unified control, diagnostics, and mode based automation. “RideControll
LabVantage Solutions Introduces LabVantage CORTEX, Advancing Its LIMS Platform for AI-Driven Laboratory Operations5.3.2026 13:30:00 CET | Press release
—Next-Generation Platform Extends LIMS with Agentic AI and Cloud-Native Automation to Improve Efficiency, Reduce Errors and Gain Deeper Insight from Data —— Learn More from LabVantage Leadership at Pittcon 2026 — LabVantage Solutions, Inc., a global provider of laboratory informatics solutions and services, today announced the launch of LabVantage CORTEX, a next-generation artificial intelligence (AI), analytics, and automation platform. The launch represents a strategic evolution of the company’s laboratory informatics portfolio, integrating advanced AI and smarter automation into the core LabVantage LIMS experience to help laboratories operate with greater accuracy, efficiency, and confidence. LabVantage CORTEX is built to support the growing demand for intelligent, automated laboratory environments across industries, including pharma and biotech, food and beverage, oil and gas, forensics, and more. LabVantage CORTEX provides a customer-centric AI analytics and automation ecosystem t
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom